- $56.06m
- $38.98m
- $0.03m
Brief: Acelrx Pharma Reports First Quarter 2023 Financial Results
AcelRx Pharmaceuticals Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: AcelRx Pharmaceuticals Says On April 26, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
AcelRx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: AcelRx Pharmaceuticals Inc Reports Quarterly Loss Per Share Of $1.00
AcelRx Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: AcelRx Pharmaceuticals And Catalent Pharma Enter Into Termination Agreement
AcelRx Pharma slides on sale of opioid pain drug
Brief: Acelrx Pharmaceuticals Announces Divestment Of Dsuvia® To Alora Pharmaceuticals
AcelRx Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Alphabet, Tesla, Nordstrom
Brief: AcelRx Pharmaceuticals Files For Offering Of Up To 748,744 Shares
Brief: Acelrx Announces $7.5 Mln Direct Offering Of Common Stock
Brief: AcelRx Pharma Says, On Nov 29, Co Got Notice From Patheon Pharma That It Intends To Terminate Manufacturing Services Agreement Between Parties - Filing
AcelRx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results, Provides Corporate Update
AcelRx Pharmaceuticals Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: AcelRx Pharmaceuticals Announces The European Launch Of Dzuveo By Its Partner, Aguettant
U.S. STOCKS ON THE MOVE-Moderna, Netflix, Visa